358369-06-9

Upstream product

• 91-16-7 1,2-dimethoxybenzene 
• 358369-11-6 2-[2-(3,4-dimethoxyphenyl)-1-methyl-2-oxoethyl]malonic acid di(tert-butyl ester) 
• 2859-78-1 4-Bromoveratrole 
• 4100-80-5 2-methylsuccinic anhydride 
• 996-82-7 sodium diethylmalonate 
• 7446-70-0 aluminium trichloride 
• 98-95-3 nitrobenzene 
• 36287-36-2 2-chloro-1-(3,4-dimethoxyphenyl)propan-1-one 

Relevant academic research and scientific papers

PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS

The compounds of a certain formula 1, in which the given substituents have the meanings as indicated in the description, are novel effective PDE4 inhibitors.

Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues

A number of 6-(3,4-dimethoxyphenyl)-4,5-dihydro-2H-pyridazin-3-ones and a novel series of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones were prepared and tested on the cGMP-inhibited phosphodiesterase (PDE3) and cAMP-specific phosphodiesterase (PDE4) enzymes. All tested compounds were found to specifically inhibit PDE4 except for pyridazinone 3b, which showed moderate PDE4 (pIC50 = 6.5) as well as PDE3 (pIC50 = 6.6) inhibitory activity. In both the pyridazinone and phthlazinone series it was found that N-substitution is beneficial for PDE4 inhibition, whereas in the pyridazinone series it also accounts for PDE4 selectivity. In the phthalazinone series, the cis-4a,5,6,7,8,8a-hexahydrophthalazinones and their corresponding 4a,5,8,8a-tetrahydro analogues showed potent PDE4 inhibitory potency (10/11c,d: pIC50 = 7.6-8.4). A molecular modeling study revealed that the cis-fused cyclohexa(e)ne rings occupy a region in space different from that occupied by the other fused (un)saturated hydrocarbon rings applied; we therefore assume that the steric interactions of these rings with the binding site play an important role in enzyme inhibition.